PCDH9抗体

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using PCDH9 mouse mAb against C6 (1) cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using PCDH9 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using PCDH9 mouse mAb (green) and negative control (red).    

  
  

Protocadherin-9 (PCDH9) is a member of the protocadherin family, a subgroup of cadherin-related transmembrane proteins involved in cell-cell adhesion, neural development, and synaptic specificity. Encoded by the *PCDH9* gene, it is primarily expressed in the central nervous system, where it regulates neuronal connectivity, axon guidance, and dendritic arborization through calcium-dependent homophilic binding. PCDH9’s extracellular domain contains multiple cadherin repeats, while its cytoplasmic domain interacts with intracellular signaling molecules, influencing cytoskeletal dynamics and synaptic plasticity.

PCDH9 antibodies are essential tools for studying its expression, localization, and function in biological systems. They are widely used in techniques like immunohistochemistry, Western blotting, and immunofluorescence to investigate PCDH9’s role in neurodevelopmental disorders, neurodegenerative diseases, and cancer. Recent studies suggest PCDH9 may act as a tumor suppressor in certain cancers, with reduced expression linked to poor prognosis. However, its mechanisms remain under exploration.

Commercial PCDH9 antibodies are typically raised against specific epitopes (e.g., extracellular or intracellular regions) and validated for species reactivity (human, mouse, rat). Researchers must verify antibody specificity using knockout controls or siRNA-based approaches, as cross-reactivity with other protocadherins is a potential concern. Understanding PCDH9’s interactions and signaling pathways could offer insights into therapeutic strategies for neurological and oncological conditions.